Health Ministry Recalls Similac Batch, Warns on Weight Loss Drug

Israel's Ministry of Health has temporarily suspended the use of a specific batch of Similac infant formula, batch number 89203N201, distributed exclusively to medical facilities. This precautionary measure was initiated after a single complaint regarding the product's quality was received. No official reports of affected infants have been documented. The affected batch is not available in retail stores. Abbott, the manufacturer, is arranging for the replacement of the recalled batch with safe alternatives. The ministry emphasized that the ban applies only to this specific series, with all other Similac products remaining safe for use.

In a separate warning, the Ministry of Health advised the public against purchasing or consuming the weight loss product G-Slim. Laboratory tests revealed the presence of sibutramine, a pharmaceutical substance with significant health risks and restricted use in many countries, including Israel. The concentration of sibutramine found in G-Slim capsules was notably high, exceeding by more than three times the levels found in previously recalled products. The danger of G-Slim has been medically confirmed, with one consumer requiring hospitalization due to chest pains and rapid heartbeat after taking the capsules. The ministry urges consumers to avoid G-Slim and to exercise caution with unregulated weight loss products that may contain undeclared active ingredients.